Filtered By:
Cancer: Cervical Cancer
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 929 results found since Jan 2013.
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis
Vaccine. 2023 Feb 14:S0264-410X(23)00160-3. doi: 10.1016/j.vaccine.2023.02.025. Online ahead of print.ABSTRACTGlobally, gender-neutral Human Papillomavirus (HPV) vaccination programmes are gaining traction. Although cervical cancer remains the most prevalent, other HPV-related cancers are increasingly recognised as important, especially among men who have sex with men. We assessed if including adolescent boys in Singapore's school-based HPV vaccination programme is cost-effective from the healthcare perspective. We adapted a World Health Organization-supported model, Papillomavirus Rapid Interface for Modelling and Economi...
Source: Vaccine - February 16, 2023 Category: Allergy & Immunology Authors: Muhammad Taufeeq Wahab Rayner Kay Jin Tan Alex R Cook Kiesha Prem Source Type: research
Parents' willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
This study aimed to assess parents' willingness to vaccinate their daughters with Human Papillomavirus vaccine and associated factors in Debre Tabor town. A community-based cross-sectional study was conducted among parents of daughters in Debre Tabor town, and a cluster sampling technique was used to select 738 study participants. A structured and interviewer-administered questionnaire was used to collect the data. Data were entered into EPI data version 4.6 and exported to SPSS version 26 for analysis. Multivariable logistic regression was done and a p-value of ≤ 0.05 was used to declare the level of significance. In th...
Source: Cancer Control - February 16, 2023 Category: Cancer & Oncology Authors: Getie Mihret Aragaw Tazeb Alemu Anteneh Saron Abeje Abiy Mulunesh Abuhay Bewota Getie Lake Aynalem Source Type: research
Prevalence of High-Risk Human Papillomavirus in Cervical Intraepithelial Neoplasia in the Pre-Vaccine Era - China, 2017-2018
China CDC Wkly. 2022 Dec 2;4(48):1083-1087. doi: 10.46234/ccdcw2022.218.ABSTRACTWHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Human papillomavirus (HPV) type-specific strategies play a key role in the prevention of cervical intraepithelial neoplasia (CIN), but evidence on the HPV type-specific prevalence in CIN is limited.WHAT IS ADDED BY THIS REPORT?: This multicentric study estimates the prevalence of high-risk HPV types in CIN cases and the associations of HPV infection patterns with high-grade CIN in China in 2017-2018.WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Population-based prevention strategies should give ...
Source: Cancer Control - February 8, 2023 Category: Cancer & Oncology Authors: Heling Bao Weihong Chen Xiaosong Zhang Hui Bi Yun Zhao Liwen Fang Shu Cong Feng Tan Linhong Wang Source Type: research
Feasibility and acceptability of self-collection of Human Papillomavirus samples for primary cervical cancer screening on the Caribbean Coast of Nicaragua: A mixed-methods study
CONCLUSION: Self-collection of samples for hrHPV testing demonstrated high acceptability and feasibility. Through concerted effort at the local, regional, and national levels, this project supported capacity building in reporting, monitoring, and surveilling cervical cancer screening across the continuum of cervical cancer control.PMID:36741739 | PMC:PMC9895854 | DOI:10.3389/fonc.2022.1020205
Source: Cancer Control - February 6, 2023 Category: Cancer & Oncology Authors: Emma McKim Mitchell Katherine M Hall Aubrey Doede Anneda Rong Michelet McLean Estrada Orlando Benito Granera Francisco Maldonado Hala Al Kallas Cassandra Bravo-Rodriguez Mariana Forero Yolande Pokam Tchuisseu Rebecca A Dillingham Source Type: research
More than cervical cancer: Understanding racial/ethnic disparities in oropharyngeal cancer outcomes among males by HPV status
Conclusions: To decrease incidence rates of late stage OPCa, HPV vaccination and possibly, HPV OPCa screening should be advocated, especially in White males. Further research to explicate possible biologic mechanisms and behaviors or comorbidities contributing to the higher OPCa mortality among Black males is needed.PMID:36696662 | DOI:10.1370/afm.20.s1.2625
Source: Annals of Family Medicine - January 25, 2023 Category: Primary Care Authors: Seiichi Villalona Jeanne Ferrante Satsuki Villalona Antoinette Stroup Source Type: research
A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer
Biomater Sci. 2023 Jan 19. doi: 10.1039/d2bm01715f. Online ahead of print.ABSTRACTHuman papilloma virus (HPV), one of the most common cancer-causing viruses, accounts for more than 90% of human anal and cervical cancers. Clinical studies have focused on adjuvant therapy with vaccines to improve therapeutic outcomes in patients with late-stage HPV-related cancers. In the present study, a mannose receptor (CD206) targeting a lithocholic acid-modified polyethylenimine (PEI) nano-adjuvant delivering the toll-like receptor 7/8 agonist, resiquimod (R848) (mLAPMi-R848), in a HPV E6- and E7-expressing TC-1 tumor murine model was d...
Source: Anal Sci - January 19, 2023 Category: Chemistry Authors: Adityanarayan Mohapatra Santhosh Kalash Rajendrakumar Kondareddy Cherukula Myong-Suk Park Sathiyamoorthy Padmanaban Arathy Vasukuty Ayeskanta Mohanty Jae Young Lee Woo Kyun Bae In-Kyu Park Source Type: research
An Update on Human Papillomavirus Vaccination in the United States
This article highlights the evidence that the HPV vaccine is a safe and highly effective way to prevent cervical cancer, with the strongest predictor of vaccine uptake being practitioner recommendation.PMID:36649341 | DOI:10.1097/AOG.0000000000005056
Source: Obstetrics and Gynecology - January 17, 2023 Category: OBGYN Authors: Teresa K L Boitano Peter W Ketch Isabel C Scarinci Warner K Huh Source Type: research
Cancer statistics, 2023
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.ABSTRACTEach year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, tra...
Source: Clinical Prostate Cancer - January 12, 2023 Category: Cancer & Oncology Authors: Rebecca L Siegel Kimberly D Miller Nikita Sandeep Wagle Ahmedin Jemal Source Type: research
